We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Rheumatoid Arthritis
  • Lupus
  • Gout
  • Psoriatic Arthritis
  • Osteoarthritis
  • Conferences
  • Topics

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • Rheumatoid Arthritis
  • Lupus
  • Gout
  • Psoriatic Arthritis
  • Osteoarthritis
  • Conferences
  • Topics

SUBSCRIBE: eNewsletter

Hypersensitivity Low in RA Biologics

  • Walter Alexander
Jan 12, 2017
  • Rheumatoid Arthritis

While the absolute rate of hypersensitivity reactions for all biologics is low among rheumatoid arthritis patients, according to a study, the administration of intravenous biologics is associated with higher hypersensitivity reaction risk, and hypersensitivity reaction risk is highest with the first or second infusion.

Although biologics approved over the last decade have revolutionized treatment options for rheumatoid arthritis patients, hypersensitivity reactions with biologics occur ranging from minimally uncomfortable to severe and life threatening.

Among biologic agents approved for rheumatoid arthritis, five target tumor necrosis factor- α (etanercept, infliximab, adalimumab, golimumab, certolizumab), others are monoclonal antibodies against CD20 (rituximab) and IL-6 (tocilizumab), and abatacept is a recombinant fusion protein that inhibits co-stimulation. Potential variations in safety profiles with respect to hypersensitivity reactions, given these agents’ structural and functional differences, have not been well studied. Prior examination of hypersensitivity reaction incidence among biologic users has largely been in small trials of homogenous patient populations or single-center experience.

In this study, led by Jeffrey R. Curtis, M.D., of the University of Alabama, researchers found that among rheumatoid arthritis patients taking biologics — rituximab, infliximab and tocilizumab were most strongly associated with hypersensitivity reactions, but the absolute incident rates for all hypersensitivity reaction events for all biologics was less than 1 percent. However, subcutaneous biologics were associated with increased risk of hypersensitivity reactions. The study appears in the Nov. 3 online issue of Arthritis Care and Research.

The retrospective cohort study is based on the evaluation of 2006-2013 fee-for-service Medicare claims data. It included 80,587 Medicare rheumatoid arthritis patients who were new users of adalimumab, certolizumab, etanercept, golimumab (n=9), infliximab (17,613), abatacept (n=15,820), rituximab (n=9,124) and tocilizumab (subcutaneous n=40, intravenous, n=5,466). The primary outcome was first occurrence of a hypersensitivity reaction during follow-up.

During the 30-day post-administration follow-up period, among the 248 hypersensitivity reactions identified, 43 (17.3%) were associated with inpatient hospitalization, 194 (78.2%) with emergency department (without hospitalization) and 11 (4.4%) with outpatient treatment. Ninety-three cases occurred within 1-day of biologic administration. One death occurred after administration of tocilizumab.

After adjustment using injectable anti-TNF during days 0-30 as the referent, infliximab (relative risk [RR]:26.9, 95% 17.4 - 41.5), tocilizumab (RR:22.2, 95% 11.6 - 42.4), rituximab (RR:18.0, 95% 8.9 - 36.2), and abatacept (RR: 7.1, 95% 3.9 – 12.8) infusions were associated with a significant higher risk of hypersensitivity reactions during 0-1 days of administration.

At the same time, methotrexate use was associated inversely with hypersensitivity reactions (0-10 mg/day versus none: RR: 0.7, 95% 0.5-0.9; 10-15 mg/day: RR: 0.5, 95% 0.3-0.8; 15-20 mg/day: RR: 0.4, 95% 0.2-0.7; >20mg/day: RR: 0.5, 0.2-1.3).

The analysis of hypersensitivity reaction frequency distribution showed also that those reactions occurring within one day of administration were more likely to happen during the first administration for abatacept (68.8%) and rituximab (43.8%). In contrast, the highest frequency of hypersensitivity reactions occurred among infliximab users with the second administration (41.7%) and the third (30.8%) among tocilizumab users.

Compared to subcutaneous biologics, infusion medications were more frequently associated with hypersensitivity reactions, with the strongest association for rituximab, followed by tocilizumab and infliximab. The cumulative incidence in the first 6 months of treatment was less than 1%, with events occurring most likely with the first or second infusions.

“Because the risk of serious hypersensitivity reactions is the highest in the first several administrations, particular vigilance needs to be paid with early administrations, yet patients remain at risk throughout the course of therapy,” the researchers wrote.

The authors cautioned further that because the analysis was conducted solely among Medicare rheumatoid arthritis patients, results may not be fully generalizable to younger patients and those covered by commercial insurance.

As reported in the journal, Arthritis Care and Research:

  • “The absolute rate and cumulative incidence over six months of hypersensitivity for all biologics was low (i.e. < 1%) among rheumatoid arthritis patients taking biologics.”
  • “However, administration of intravenous biologics was associated with an increased risk of hypersensitivity as compared to subcutaneous TNFi therapy.”
  • “Hypersensitivity events were more likely to occur after the first or second infusions.”
  • “Infliximab, rituximab and tocilizumab were most strongly associated with hypersensitivity events.”

 

Disclosures: 

Funding: Agency for Healthcare Research and Quality (AHRQ) (R01 HS018517) and the Patient Centered Outcomes Research Institute (PCORI)

Dr. Yun was supported by grant 1 K12 HS021694 from AHRQ and has research grant from Amgen for unrelated work

JRC receives support from the NIH P60 (AR064172) and has research grants and/or consulting for unrelated work with Amgen, BMS, CORRONA, Janssen, Pfizer, UCB

JDL: Research grants and/or consulting for unrelated work with Shire, Takeda, Centocor, Amgen, Millennium Pharmaceuticals, Pfizer, Abbott, Prometheus, Nestle, Lilly, Gilead, Merck, Janssen

KGS: Research grants and/or consulting for unrelated work with Roche/Genentech, Abbvie, BMS, Bayer, Merck

References: 

Huifeng Yun, Fenglong Xie, et al. “The Risk of Hypersensitivity Associated with Biologic Use among Medicare Patients with Rheumatoid Arthritis,” Arthritis Care & Research. Nov. 3, 2016. DOI 10.1002/acr.23141.

 

 

Related Articles

  • Predictors of Methotrexate Failure in Inflammatory Polyarthritis
  • Statins No Silver Bullet in RA
  • Vaccine Efficacy in Rheumatoid Arthritis
  • Vitamin and Mineral Supplementation in Rheumatoid Arthritis: A Look at the Evidence
  • 6 Top Rheumatology Apps for Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Lupus
Rheumatoid Arthritis
Psoriatic Arthritis
Spondyloarthritis
There is currently no available content. Please check back soon.
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.